ArticleBMC neurology2026
Risk factors for cerebral infarction in patients with rheumatoid arthritis: a retrospective case-control study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveTo investigate the risk factors, including relevant autoantibodies, for cerebral infarction in patients with rheumatoid arthritis (RA).
methodsThirty-nine RA patients with cerebral infarction admitted to Weifang People's Hospital since January 2010 were selected as the RA cerebral infarction group. Seventy-two RA patients without cerebral infarction hospitalized during the same period were randomly selected as the RA non-cerebral infarction group. Gender, age, RA disease duration, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibody, anti-Sjögren's syndrome antigen A (anti-SSA) antibody, anti-Sjögren's syndrome antigen B (anti-SSB) antibody, Erythrocyte Sedimentation Rate(ESR), C-Reactive Protein(CRP), swollen joint count(SJC), tender joint count(TJC), patient global assessment(PGA), physician's global assessment (PhGA), as well as the presence of comorbid hypertension, diabetes, and smoking status were compared between the two groups. Additionally, Disease Activity Score-28 using ESR (DAS28-ESR), Disease Activity Score-28 using CRP(DAS28-CRP), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) were compared between the two groups.
resultsUnivariate analysis showed that there were statistically significant differences between the two groups in DAS28-ESR, DAS28-CRP, CRP levels, SJC, PGA, PhGA, SDAI, CDAI, anti-SSB positivity, and comorbid hypertension (P < 0.05), while no statistically significant differences were found in the remaining variables (P > 0.05). Multivariate logistic regression analysis revealed that anti-SSB positivity, SJC ≥ 11, and CRP ≥ 26.85 mg/l were independent risk factors for the occurrence of cerebral infarction in patients with rheumatoid arthritis. The most common clinical manifestation in the RA with cerebral infarction group was hemiplegia.
conclusionPositivity for anti-SSB antibody, SJC ≥ 11, and CRP ≥ 26.85 mg/l were independent risk factors for the occurrence of cerebral infarction in patients with rheumatoid arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.